Global Leading Market Research Publisher QYResearch announces the release of its latest report “Vitamin B12 Injection – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Vitamin B12 Injection market, including market size, share, demand, industry development status, and forecasts for the next few years.
For endocrinologists, neurologists, gastroenterologists, and primary care physicians managing patients with vitamin B12 deficiency, the choice between oral and parenteral therapy is often determined by the underlying cause of deficiency. Patients with pernicious anemia, gastric surgery, inflammatory bowel disease, or other conditions affecting absorption require injectable vitamin B12 to bypass gastrointestinal barriers and ensure adequate systemic delivery. Vitamin B12 injection—available as cyanocobalamin or hydroxocobalamin—provides reliable, predictable supplementation for patients who cannot absorb oral forms, offering essential support for red blood cell formation, neurological function, and overall metabolic health. This report delivers authoritative market intelligence for stakeholders navigating the essential role of injectable B12 in clinical practice.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6089025/vitamin-b12-injection
Market Scale and Growth Trajectory
The global market for Vitamin B12 Injection was estimated to be worth US$ 938 million in 2025 and is projected to reach US$ 1296 million, growing at a CAGR of 4.8% from 2026 to 2032. This steady growth reflects the sustained demand for injectable B12 therapy driven by the aging population, the increasing prevalence of conditions affecting B12 absorption, and the growing recognition of B12 deficiency as a common and treatable condition. The market’s stable growth trajectory is supported by the essential nature of this therapy for patients with pernicious anemia and other malabsorptive disorders, ensuring continued utilization across healthcare settings.
Key Industry Keywords:
- Pernicious Anemia
- Cyanocobalamin
- Hydroxocobalamin
- Malabsorption Disorders
- Parenteral Nutrition
Defining Vitamin B12 Injection: Formulation and Clinical Indications
A sterile aqueous solution containing cyanocobalamin or methylcobalamin as the active ingredient, indicated for pernicious anemia, peripheral neuropathy, and B12 deficiency. Manufactured under GMP conditions to ensure sterility, pyrogen-free status, and pH stability (4.0-7.0), it is packaged in single-dose ampoules or multi-dose vials, with pretreatment assessment of cobalamin metabolism required.
Key Formulations:
- Cyanocobalamin Injection: The most widely used form globally, cyanocobalamin is a synthetic form of vitamin B12 that is stable, cost-effective, and readily converted to active coenzyme forms in the body. It is indicated for pernicious anemia, vitamin B12 deficiency due to malabsorption, and nutritional deficiency.
- Hydroxocobalamin Injection: A naturally occurring form of B12 with higher tissue retention than cyanocobalamin. Hydroxocobalamin is the preferred form in some regions (particularly Europe) for pernicious anemia due to its longer duration of action and less frequent dosing requirements. It also has a unique indication for cyanide poisoning.
Clinical Indications:
- Pernicious Anemia: An autoimmune condition characterized by impaired absorption of vitamin B12 due to deficiency of intrinsic factor. Pernicious anemia requires lifelong injectable B12 therapy, representing the core patient population for this product category.
- B12 Deficiency Due to Malabsorption: Conditions including gastric surgery (bariatric surgery, gastrectomy), Crohn’s disease, celiac disease, and chronic pancreatitis can impair B12 absorption, necessitating parenteral supplementation.
- Peripheral Neuropathy: B12 deficiency is a recognized cause of peripheral neuropathy, and injectable B12 is used both for deficiency-related neuropathy and, in some settings, as adjunctive therapy for other neuropathic conditions.
- Diabetes: Metformin, a first-line diabetes medication, can cause B12 deficiency in long-term users, creating a population requiring supplementation.
- Malnutrition: Nutritional deficiency in elderly populations, individuals with dietary restrictions, or those with inadequate intake may require parenteral therapy.
- Gastric Disease: Post-surgical or disease-related impairment of B12 absorption.
Industry Development Characteristics: Market Segmentation and Competitive Landscape
Market Segmentation by Type
- Cyanocobalamin Injection: The largest segment, representing the standard of care in the United States and many global markets. Cyanocobalamin’s stability, established manufacturing processes, and cost-effectiveness support its dominant market position.
- Hydroxocobalamin Injection: A significant segment, particularly in European markets where it is often the preferred form for pernicious anemia. Hydroxocobalamin’s longer duration of action allows for less frequent dosing (every 2-3 months versus monthly) and higher tissue retention.
Market Segmentation by Application
- Pernicious Anemia: The core and most established application, requiring lifelong injectable therapy. This patient population represents predictable, sustained demand.
- Diabetes: A growing application segment driven by the recognition of metformin-associated B12 deficiency and increased screening for deficiency in diabetic populations.
- Gastric Disease: Including post-bariatric surgery patients, gastrectomy, and other gastric conditions affecting intrinsic factor production.
- Malnutrition: Including elderly patients with inadequate dietary intake, individuals with eating disorders, and those with chronic conditions affecting nutritional status.
- Others: Including neurological applications, fatigue management, and adjunctive therapy for various conditions.
Competitive Landscape
The vitamin B12 injection market features a diverse range of manufacturers including established pharmaceutical companies, specialty injectable manufacturers, and regional producers:
- North American: AdvaCare Pharma, American Regent, Meitheal Pharmaceuticals, Hikma Pharmaceuticals USA, Olympia Pharmaceuticals, Vitruvias Therapeutics, Empower, Actavis, Sola Pharmaceuticals, Somerset Pharma, Padagis, Accord Healthcare, Lifestar Pharma, Medisca
- European: EUROAPI
- Asian: CSPC, Nanjing King-Friend Biochemical Pharmaceutical, Viwit, Panbiotic Laboratories, Tiantaimount Pharmaceutical, Shanghaipujinlinzhou Pharmacy
The market is characterized by multiple generic manufacturers following patent expiration, resulting in competitive pricing and widespread availability.
Industry Trends: The Shift Toward Preventive and Early Intervention
Increased Screening and Early Detection
A defining characteristic of current market development is the increased awareness of vitamin B12 deficiency and expanded screening practices. Studies indicate that B12 deficiency affects approximately 6-15% of the general population, with higher prevalence among elderly individuals (up to 20%) and specific patient populations. Increased screening, particularly in patients with diabetes on metformin, gastrointestinal conditions, and neurological symptoms, has expanded the diagnosed patient population requiring treatment.
Post-Bariatric Surgery Population
The rising prevalence of bariatric surgery—with over 200,000 procedures performed annually in the United States alone—has created a significant new patient population requiring lifelong B12 supplementation. Gastric bypass and sleeve gastrectomy procedures substantially reduce B12 absorption, making injectable therapy the preferred option for many post-surgical patients. This demographic trend supports sustained market growth.
A recent case study from a major bariatric surgery center illustrates this trend. The center performs approximately 800 bariatric procedures annually, with all patients receiving preoperative counseling on lifelong vitamin supplementation. Postoperative protocols recommend injectable B12 for patients with certain surgical types or those who develop deficiency despite oral supplementation. This patient cohort represents predictable, long-term demand for injectable B12 products.
Exclusive Analyst Observation: The Injectable Advantage in Malabsorption
Our ongoing market monitoring reveals that injectable vitamin B12 occupies a distinct and essential niche within the broader B12 supplementation market. While oral B12 supplements are widely available and sufficient for many individuals, patients with intrinsic factor deficiency, gastric surgery, or significant malabsorption require injectable forms to achieve therapeutic levels. This clinical reality ensures stable demand for injectable products regardless of the availability of oral alternatives. The injectable market is thus less susceptible to competition from over-the-counter oral supplements than other vitamin markets.
Technical Challenges and Policy Drivers
Manufacturing Standards: Vitamin B12 injection is manufactured under strict Good Manufacturing Practice (GMP) conditions to ensure sterility, pyrogen-free status, and pH stability (4.0-7.0). The product is packaged in single-dose ampoules or multi-dose vials, with preservatives included in multi-dose formulations to maintain sterility after opening.
Regulatory Landscape: Vitamin B12 injection is regulated as a prescription drug in most markets. Pretreatment assessment of cobalamin metabolism—including measurement of serum B12 levels, methylmalonic acid, and homocysteine—is recommended to confirm deficiency before initiating therapy. This diagnostic requirement supports appropriate utilization.
Reimbursement: In the United States, injectable B12 is covered under Medicare Part B for pernicious anemia and other qualifying indications. Commercial insurance similarly covers the product for diagnosed deficiency conditions.
Strategic Implications for Industry Participants
For pharmaceutical manufacturers, healthcare providers, and investors, several considerations emerge from current market dynamics:
Reliable Supply Essential: As an essential medicine for patients with pernicious anemia and other malabsorptive conditions, consistent supply and quality are critical. Manufacturers with robust supply chains capture stable market positions.
Differentiation Through Formulation: While the market is genericized, differentiation through formulation (hydroxocobalamin vs. cyanocobalamin), preservative systems, and packaging configurations offers opportunities for product positioning.
Patient Education and Compliance: Ensuring patients understand the necessity of lifelong therapy and the importance of consistent dosing supports treatment adherence and sustained market demand.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
